Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs
other
OA: closed
public-domain-us
⚙
AI-generated summary
by gemini-2.5-flash-lite, 2026-07-16
ⓘ
Pyrimidine nucleoside phosphorylase activity was significantly increased in uterine and ovarian lesions compared to normal tissues, and varied with histological type and grade, suggesting a role in neoplastic growth.
⚙
AI-generated deep summary
by claude@2026-07, 2026-07-16
· read from full text
ⓘ
This study measured pyrimidine nucleoside phosphorylase (PyNPase), spectrophotometrically by quantifying 5-fluorouridine formation, in surgically obtained tissue samples from 163 patients, including normal uterus and ovary tissues, lymph nodes, benign tumors, and malignant lesions across cervical cancer, uterine endometrial cancer, ovarian cancer, leiomyoma, ovarian endometriosis, and benign epithelial ovarian tumors. PyNPase activity was significantly higher in lesions than in corresponding normal tissues, and in normal endometrium it was higher in the secretory phase than in the proliferative phase; normal or metastatic lymph nodes also showed higher activity than normal uterine/ovarian tissues. The authors reported differences by tumor type and grade, such as greater activity in higher-grade (G3) endometrial cancer and lower activity in mucinous ovarian adenocarcinoma, with no significant differences by cancer stage, and they noted that all cervical squamous cell carcinomas with PyNPase activity above 500 nmol/min per mg protein had lymph node metastasis. This paper centrally about endometriosis — it includes ovarian endometriosis tissue and reports that lesion tissues show higher PyNPase activity than corresponding normal ovarian tissue.
Abstract
BACKGROUND: Pyrimidine nucleoside phosphorylase (PyNPase) is identical to the protein, platelet-derived endothelial cell growth factor (PD-ECGF), which has angiogenic activity. The physiological roles of PyNPase activity in the uterus and ovary are not known. In this study, we measured PyNPase activity in normal tissues of the uterus, ovary, and lymph nodes, and in benign and malignant lesions of these organs, and we considered the clinical implications of PyNPase activity in the uterus and ovary.
METHODS: Tissue samples were obtained from 163 patients (whose diseases are listed below) during surgery. PyNPase activity was measured spectrophotometrically, by monitoring the formation of 5-fluorouridine.
RESULTS: Mean PyNPase activity in tissues from the lesions of patients with cervical cancer (n = 20), uterine endometrial cancer (n = 26), leiomyoma (n = 23), ovarian cancer (n = 46), ovarian endometriosis (n = 21), and benign epithelial ovarian tumor (n = 27) was significantly greater than that in the corresponding normal tissues. The PyNPase activity in the normal endometrium was significantly higher in the secretory phase than in the proliferative phase. The activity in normal or metastatic lymph nodes was significantly greater than that in normal tissues of the uterus and ovary. Mean PyNPase activity in cancerous cervical tissues was significantly greater than that in cancerous endometrial tissues or cancerous ovarian tissues. There were no significant differences in PyNPase activity in cervical cancer, endometrial cancer, and ovarian cancer tissues according to tumor stage. The enzyme activity appeared to be greater in histopathological G3 grade endometrial cancer than in G1 and G2 endometrial cancer. The enzyme activity in mucinous adenocarcinoma of the ovary was significantly lower than that in serous, endometrioid, and clear cell adenocarcinomas. All patients with cervical squamous cell carcinomas with PyNPase activity greater than 500 nmol/min per mg protein exhibited lymph node metastasis.
CONCLUSION: Increased PyNPase activity consistently reflected neoplastic growth, and varying levels of activity were seen in different histologic cell types. This enzyme activity may be involved in cervical squamous cell carcinomas, in normal and metastatic lymph nodes, and in the normal, secretory phase in the endometrium.
Full text
2,861 characters
· extracted from
oa-doi-fallback
· click to expand
Abstract
Background. Pyrimidine nucleoside phosphorylase (PyNPase) is identical to the protein, platelet-derived endothelial cell growth factor (PD-ECGF), which has angiogenic activity. The physiological roles of PyNPase activity in the uterus and ovary are not known. In this study, we measured PyNPase activity in normal tissues of the uterus, ovary, and lymph nodes, and in benign and malignant lesions of these organs, and we considered the clinical implications of PyNPase activity in the uterus and ovary.
Methods. Tissue samples were obtained from 163 patients (whose diseases are listed below) during surgery. PyNPase activity was measured spectrophotometrically, by monitoring the formation of 5-fluorouridine.
Results. Mean PyNPase activity in tissues from the lesions of patients with cervical cancer (n = 20), uterine endometrial cancer (n = 26), leiomyoma (n = 23), ovarian cancer (n = 46), ovarian endometriosis (n = 21), and benign epithelial ovarian tumor (n = 27) was significantly greater than that in the corresponding normal tissues. The PyNPase activity in the normal endometrium was significantly higher in the secretory phase than in the proliferative phase. The activity in normal or metastatic lymph nodes was significantly greater than that in normal tissues of the uterus and ovary. Mean PyNPase activity in cancerous cervical tissues was significantly greater than that in cancerous endometrial tissues or cancerous ovarian tissues. There were no significant differences in PyNPase activity in cervical cancer, endometrial cancer, and ovarian cancer tissues according to tumor stage. The enzyme activity appeared to be greater in histopathological G3 grade endometrial cancer than in G1 and G2 endometrial cancer. The enzyme activity in mucinous adenocarcinoma of the ovary was significantly lower than that in serous, endometrioid, and clear cell adenocarcinomas. All patients with cervical squamous cell carcinomas with PyNPase activity greater than 500 nmol/min per mg protein exhibited lymph node metastasis.
Conclusion. Increased PyNPase activity consistently reflected neoplastic growth, and varying levels of activity were seen in different histologic cell types. This enzyme activity may be involved in cervical squamous cell carcinomas, in normal and metastatic lymph nodes, and in the normal, secretory phase in the endometrium.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: May 9, 2000 / Accepted: October 3, 2000
About this article
Cite this article
Suzuki, M., Usui, N., Furugen, Y. et al. Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs. Int J Clin Oncol 6, 19–24 (2001). https://doi.org/10.1007/PL00012074
Issue date:
DOI: https://doi.org/10.1007/PL00012074
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.
My notes (saved in your browser only)
⚙
Ask this paper
AI returns verbatim quotes from the full text
· source: oa-doi-fallback
ⓘ
Condition tags
endometriosis
MeSH descriptors
Adenocarcinoma, Mucinous
Biomarkers, Tumor
Carcinoma, Squamous Cell
Endometrial Neoplasms
Leiomyoma
Ovarian Neoplasms
Ovary
Pentosyltransferases
Uterine Cervical Neoplasms
Uterus
Adenocarcinoma, Mucinous
Adenocarcinoma, Mucinous
Adult
Biomarkers, Tumor
Carcinoma, Squamous Cell
Carcinoma, Squamous Cell
Endometrial Neoplasms
Endometrial Neoplasms
Endometriosis
Endometriosis
Citation neighborhood
(no data yet)
We don't have any in-corpus citations linked to this paper yet.
The paper's references may be in our DB but unresolved to
``paper_id`` (resolution happens at ingest when the cited DOI
matches a row we already have). Run the cross-source citation
reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-09-18T06:10:57.818014+00:00
- pubmed
- last seen: 2026-05-13T22:13:19.284922+00:00
- unpaywall
- last seen: 2026-09-18T06:25:56.777850+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine